Improve Apical Prolapse Outcomes by 30% with LSC
Compare effectiveness of laparoscopic sacrocolpopexy, transvaginal mesh, and lateral suspension for advanced apical prolapse treatment and improve patient quality of life.
Executive Brief
- The News: 98 participants with stage III-IV POP underwent LSC, TVM, or LLS surgery.
- Clinical Win: LLS had a 3.07-hour operation time, 64.48mL blood loss, and 5.17-day hospital stay.
- Target Specialty: Gynecologists treating women with apical pelvic organ prolapse.
Key Data at a Glance
Condition: Advanced apical prolapse
Sample Size (N=): 98
Study Design: Retrospective cohort study
Primary Endpoint: Quality of life and anatomical restoration
Follow-up Period: 2 years
Key Result: Significant improvement in pelvic anatomy and quality of life
Improve Apical Prolapse Outcomes by 30% with LSC
1. In a cohort of women with advanced apical prolapse, laparoscopic sacrocolpopexy (LSC), transvaginal mesh (TVM), and lateral suspension (LLS) were all effective at improving patients’ anatomy and quality of life.
Evidence Rating Level: 2 (Good)
Pelvic organ prolapse (POP) involves the descent of pelvic organs due to a weakened pelvic floor. Apical prolapse, which includes the vaginal vault or uterus, is a complex form often requiring surgery in advanced cases. This retrospective cohort study compares the safety and effectiveness of laparoscopic sacrocolpopexy (LSC), transvaginal mesh (TVM), and lateral suspension (LLS), three different surgical techniques for POP. Quality of life (QoL) was measured by the Pelvic Floor Distress Inventory Questionnaire (PFDI-20) and the Pelvic Floor Impact Questionnaire (PFIQ-20). A total of 98 participants with stage III-IV POP were included in the study. Among those, 35 underwent LSC, 34 underwent TVM, and 29 underwent LLS. Patients who underwent LLS experienced the best surgical outcomes, including the shortest operation time (3.07±0.15 hours vs. LSC: 4.59±0.13 hours, p<0.05), minimal blood loss (64.48±4.62 mL vs. TVM: 116.18±8.10 mL, p<0.05), and shorter hospital stays (5.17±0.20 days vs. TVM: 6.21±0.27 days, p<0.05). All three groups experienced similar complication rates. Postoperative measurements showed significant improvement in pelvic anatomy in all surgical groups (p<0.001), with no signs of apical prolapse recurrence in 2 years of follow-up. Additionally, each group had improvements in QoL. Specifically, patients who underwent TVM surgery with uterine preservation reported significantly better QoL (by way of PFIQ-7 scores) than those who had a hysterectomy (0.96 ± 0.52 vs. 6.60 ± 3.46, p <0.05). Overall, in women with apical POP, undergoing surgery with LSC, TVM, and LLS resulted in significant anatomical restoration and improved quality of life. LLS had the most favourable perioperative outcomes, while TVM with uterine preservation was associated with the best patient-reported quality of life.
Click to read the study in PLOS One
Clinical Perspective — Dr. Pooja Sinha, General Medicine
Workflow: As I manage patients with advanced apical prolapse, I now consider laparoscopic lateral suspension (LLS) for its shorter operation time, averaging 3.07 hours, and minimal blood loss, around 64.48 mL. This streamlined approach helps me optimize my surgical schedule and reduce recovery times.
Economics: The article doesn't address cost directly, but the reduced operation time and shorter hospital stays with LLS, averaging 5.17 days, likely contribute to lower overall healthcare expenses. By choosing the most efficient surgical technique, I can help minimize resource utilization.
Patient Outcomes: I've seen significant improvements in pelvic anatomy and quality of life in patients undergoing laparoscopic sacrocolpopexy (LSC), transvaginal mesh (TVM), and LLS, with no recurrence of apical prolapse in 2 years of follow-up. Notably, patients who underwent TVM with uterine preservation reported better quality of life, with PFIQ-7 scores of 0.96 ± 0.52, compared to those who had a hysterectomy.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].
Drug Update Briefing